(AORT) Artivion - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 1.090m USD | Total Return: -20.6% in 12m
Avg Turnover: 17.3M
Qual. Beats: 0
Rev. Trend: 98.6%
Qual. Beats: 0
Warnings
P/E ratio 89.8
Share dilution 17.8% YoY
Below Avwap Earnings
Tailwinds
No distinct edge detected
Artivion, Inc. (AORT) specializes in the manufacturing and distribution of medical devices and implantable human tissues focused on aortic and cardiac surgery. Its portfolio includes prosthetic heart valves, stent graft systems, surgical sealants, and cryopreserved human tissues. Formerly known as CryoLife, the company rebranded in 2022 to reflect its specialized focus on the treatment of aortic disease.
The company operates within the cardiovascular medical device sector, a market characterized by high regulatory barriers and significant research and development requirements. Artivion utilizes a direct sales model to market its proprietary technologies, such as On-X pyrolytic carbon valves and BioGlue surgical sealant, directly to cardiac and vascular surgeons.
Investors can utilize ValueRay to further analyze the companys competitive positioning and valuation metrics. Headquartered in Georgia, Artivion maintains a global distribution network to support its diverse range of endovascular and open-surgical solutions.
- Aortic stent graft portfolio expansion drives market share gains in European markets
- On-X heart valve sales volume fluctuates based on global cardiac surgery demand
- Regulatory approval timelines for NEXUS stent graft system impact long-term revenue growth
- BioGlue surgical sealant adoption rates determine core specialty device segment profitability
- High research and development expenditures influence quarterly operating margins and cash flow
| Net Income: 11.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 1.51 > 1.0 |
| NWC/Revenue: 46.09% < 20% (prev 60.33%; Δ -14.25% < -1%) |
| CFO/TA 0.06 > 3% & CFO 56.2m > Net Income 11.7m |
| Net Debt (245.2m) to EBITDA (61.9m): 3.96 < 3 |
| Current Ratio: 3.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.7m) vs 12m ago 17.76% < -2% |
| Gross Margin: 62.94% > 18% (prev 0.64%; Δ 6.23k% > 0.5%) |
| Asset Turnover: 54.79% > 50% (prev 49.31%; Δ 5.49% > 0%) |
| Interest Coverage Ratio: 1.59 > 6 (EBITDA TTM 61.9m / Interest Expense TTM 24.3m) |
| A: 0.24 (Total Current Assets 304.1m - Total Current Liabilities 92.7m) / Total Assets 883.2m |
| B: -0.06 (Retained Earnings -50.1m / Total Assets 883.2m) |
| C: 0.05 (EBIT TTM 38.6m / Avg Total Assets 837.2m) |
| D: -0.14 (Book Value of Equity -61.1m / Total Liabilities 432.7m) |
| Altman-Z'' = 1.55 = BB |
| DSRI: 0.94 (Receivables 105.6m/95.8m, Revenue 458.7m/390.1m) |
| GMI: 1.02 (GM 62.94% / 63.94%) |
| AQI: 1.00 (AQ_t 0.54 / AQ_t-1 0.54) |
| SGI: 1.18 (Revenue 458.7m / 390.1m) |
| TATA: -0.05 (NI 11.7m - CFO 56.2m) / TA 883.2m) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at USD 23.19 with a total of 534,081 shares traded.
Over the past week, the price has changed by -2.40%,
over one month by -37.38%,
over three months by -39.10% and
over the past year by -20.61%.
Artivion has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy AORT.
- StrongBuy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 42 | 81.1% |
P/E Trailing = 89.84
P/E Forward = 140.8451
P/S = 2.377
P/B = 2.4203
P/EG = 181.5
Revenue TTM = 458.7m USD
EBIT TTM = 38.6m USD
EBITDA TTM = 61.9m USD
Long Term Debt = 215.4m USD (from longTermDebt, last quarter)
Short Term Debt = 5.53m USD (from shortTermDebt, last quarter)
Debt = 301.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 42.8m
Net Debt = 245.2m USD (calculated: Debt 301.0m - CCE 55.8m)
Enterprise Value = 1.34b USD (1.09b + Debt 301.0m - CCE 55.8m)
Interest Coverage Ratio = 1.59 (Ebit TTM 38.6m / Interest Expense TTM 24.3m)
EV/FCF = 104.1x (Enterprise Value 1.34b / FCF TTM 12.8m)
FCF Yield = 0.96% (FCF TTM 12.8m / Enterprise Value 1.34b)
FCF Margin = 2.80% (FCF TTM 12.8m / Revenue TTM 458.7m)
Net Margin = 2.55% (Net Income TTM 11.7m / Revenue TTM 458.7m)
Gross Margin = 62.94% ((Revenue TTM 458.7m - Cost of Revenue TTM 170.0m) / Revenue TTM)
Gross Margin QoQ = 61.49% (prev 60.06%)
Tobins Q-Ratio = 1.51 (Enterprise Value 1.34b / Total Assets 883.2m)
Interest Expense / Debt = 8.07% (Interest Expense 24.3m / Debt 301.0m)
Taxrate = 33.91% (5.01m / 14.8m)
NOPAT = 25.5m (EBIT 38.6m * (1 - 33.91%))
Current Ratio = 3.28 (Total Current Assets 304.1m / Total Current Liabilities 92.7m)
Debt / Equity = 0.67 (Debt 301.0m / totalStockholderEquity, last quarter 450.5m)
Debt / EBITDA = 3.96 (Net Debt 245.2m / EBITDA 61.9m)
Debt / FCF = 19.11 (Net Debt 245.2m / FCF TTM 12.8m)
Total Stockholder Equity = 439.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.40% (Net Income 11.7m / Total Assets 883.2m)
RoE = 2.39% (Net Income TTM 11.7m / Total Stockholder Equity 489.4m)
RoCE = 5.48% (EBIT 38.6m / Capital Employed (Equity 489.4m + L.T.Debt 215.4m))
RoIC = 3.20% (NOPAT 25.5m / Invested Capital 796.0m)
WACC = 8.19% (E(1.09b)/V(1.39b) * Re(8.98%) + D(301.0m)/V(1.39b) * Rd(8.07%) * (1-Tc(0.34)))
Discount Rate = 8.98% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 77.78 | Cagr: 9.08%
[DCF] Terminal Value 75.44% ; FCFF base≈12.8m ; Y1≈12.9m ; Y5≈13.6m
[DCF] Fair Price = N/A (negative equity: EV 212.3m - Net Debt 245.2m = -32.9m; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.20 | # QB: 0
Revenue Correlation: 98.60 | Revenue CAGR: 11.60% | SUE: 0.19 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.11 | Chg30d=-47.12% | Revisions=N/A | Analysts=6
EPS next Quarter (2026-09-30): EPS=0.12 | Chg30d=-44.72% | Revisions=N/A | Analysts=6
EPS current Year (2026-12-31): EPS=0.49 | Chg30d=-39.25% | Revisions=-20% | GrowthEPS=-21.7% | GrowthRev=+10.2%
EPS next Year (2027-12-31): EPS=0.77 | Chg30d=-33.11% | Revisions=-20% | GrowthEPS=+56.8% | GrowthRev=+11.0%
[Analyst] Revisions Ratio: -20%